Horsfield, K., Nicholls, A., Cumming, G., Hume, M., and Prowse, K. (1977) . Thorax, 32, [250] [251] [252] [253] . Treatment of pulmonary aspergillosis with di-iodohydroxyquinoline. Thirteen patients with a clinical diagnosis of pulmonary aspergillosis were treated with the anti-amoebic drug di-iodohydroxyquinoline, 1500-1800 mg/day orally, for 20 days. All were precipitin positive before treatment and all but one became negative after treatment. Sputum became negative in all of the 10 patients in whom it had been positive before treatment. Clinical improvement was marked in four patients, moderate in three, and slight in three, no change occurring in the remaining three. These results suggest that di-iodohydroxyquinoline may be of value in the treatment of pulmonary aspergillosis.
The treatment of fungal infections of the lungs is in many cases unsatisfactory; the report by Jesiotr (1973) of the use of emetine hydrochloride in pulmonary aspergillosis was therefore of considerable interest. Emetine has to be given by injection and is potentially toxic, and this prompted us to investigate the use of another anti-amoebic agent, di-iodohydroxyquinoline. In this paper we report 13 cases of pulmonary aspergillosis treated with this drug. No attempt was made to carry out a controlled trial; this was a preliminary investigation to see whether the drug might be of any therapeutic value.
Methods
The activity of di-iodohydroxyquinoline (DIHQ) against aspergillus was first tested in vitro. Agar plates were poured using 10 ml aliquots of Sabouraud's dextrose agar (Oxoid) Table 1 shows a summary of the results of treatment with respect to skin tests, pulmonary function tests, and degree of clinical improvement. Four patients were markedly improved, three moderately, three slightly, and three not at all. Table 2 shows the results of examination of the sputum for A. fumigatus and Table 3 the results of the precipitin tests.
Discussion
In pulmonary aspergillosis the clinical features, radiographic appearances, skin test, precipitins, and sputum culture are not consistently related to each other and may vary independently and apparently spontaneously. Assessment of the response to therapy is therefore very difficult, but the fact that 12 out of 13 patients became precipitin negative, and that all of the 10 patients with positive sputum became culture negative suggests that the treatment did in fact have some effect. A very gratifying degree of improvement occurred in patients 1, 2, 7, and 8, in three of them after years of disability, and it seems unlikely that this would have occurred by chance. In another six patients slight to moderate improvement was noted, part of which may have been due to concomitant steroid therapy, and part of which was subjective. Nevertheless some real benefit was obtained in these patients. Patients 1 and 4 were on prednisolone, and patient 2 on ACTH while taking DIHQ, but since these patients remained precipitin negative after cessation of steroid therapy and since their loss of reactivity was absolute, it was not felt that the negative tests were a consequence of steroid modification of their response. DIHQ is easily taken by mouth and has few toxic effects; only one easily controlled skin rash occurred during treatment (patient 1). One difficulty is that the drug is irregularly absorbed, and as no attempt was made to monitor blood levels we do not know whether therapeutic levels were achieved or not.
The results of this study suggest that diiodohydroxyquinoline may be of value in the treatment of pulmonary aspergillosis, and possibly of other fungal infections as well. It would be of great help if a reliably absorbed preparation could be developed.
